It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
In need of quick funds? Discover ways to get cash instantly from bank services to meet your urgent needs.
21,071 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Analogs chip stocks rebound as demand stabilizes and inventories tighten, signaling a cycle turn for the semiconducto...
Bitcoin has pulled back sharply from recent highs, leaving both new and seasoned investors wondering what comes next....
XDTE has drawn attention with a striking headline yield from zero-day-to-expiration options. This report examines the...
As market conditions shift in 2026, investors are weighing cheaper covered call ETFs against XYLD. Four funds stand o...
Investing in tomorrow’s energy tech can feel risky. This article outlines how a compact, early-stage stock could grow...
Walmart and Costco together account for about 28.7% of XLP’s assets, tightening concentration and raising questions a...
A surge in crypto funding surging again accompanies a strategic pivot by major VCs toward infrastructure and tokenize...
Hims & Hers Health announces a major acquisition of Australian digital health firm Eucalyptus, valued at up to $1.15 ...
CrowdStrike accelerates an acquisition push as Palo Alto Networks doubles down on platform strategy. Both leaders rep...
A major partnership reshapes Novo Nordisk's growth trajectory. This deep dive explains what the Vivtex deal means for...
Nvidia topped quarterly estimates with a sizable revenue beat and raised guidance, yet its stock slipped as traders w...